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Abstract 
Conventional suspension pressurised metered dose inhalers (pMDIs) suffer not only from 
delivering small amounts of a drug to the lungs, but also the inhaled dose scatters all over the 
lung regions.  This results in much less of the desired dose being delivered to regions of the 
lungs.  This study aimed to improve the aerosol performance of suspension pMDIs by 
producing primary particles with narrow size distributions.  Inkjet spray drying was used to 
produce respirable particles of salbutamol sulphate.  The Next Generation Impactor (NGI) 
was used to determine the aerosol particle size distribution and fine particle fraction (FPF).  
Furthermore, oropharyngeal models were used with the NGI to compare the aerosol 
performances of a pMDI with monodisperse primary particles and a conventional pMDI.  
Monodisperse primary particles in pMDIs showed significantly narrower aerosol particle size 
distributions than pMDIs containing polydisperse primary particles.  Monodisperse pMDIs 
showed aerosol deposition on a single stage of the NGI as high as 41.75±5.76%, while this 
was 29.37±6.79% for a polydisperse pMDI.  Narrow size distribution was crucial to achieve a 
high FPF (49.31±8.16%) for primary particles greater than 2µm.  Only small polydisperse 
primary particles with sizes such as 0.65±0.28µm achieved a high FPF with (68.94±6.22%) 
or without (53.95±4.59%) a spacer.  Oropharyngeal models also indicated a narrower aerosol 
particle size distribution for a pMDI containing monodisperse primary particles compared to 
a conventional pMDI.  It is concluded that, pMDIs formulated with monodisperse primary 
particles show higher FPFs that may target desired regions of the lungs more effectively than 
polydisperse pMDIs. 
 
Key Words: Pressurised metered dose inhalers, Monodisperse particles, Spray drying, Inkjet, 
Oropharyngeal models 
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Introduction 
Monodisperse aerosol generators have been used to determine the most effective particle size 
of drugs such as beclomethasone dipropionate or salbutamol sulphate in the treatment of 
pulmonary disease.1,2  A previous work suggested that 30 µg of monodisperse salbutamol 
sulphate aerosol particles with the aerodynamic diameter of 6 µm (inhaled from a tank) might 
have better bronchodilation effects than a 200 µg dose of a conventional pressurised metered 
dose inhaler.1  The desire to favour the deposition of inhaled drug particles in the central or 
deep lungs was the basis of developing handheld inhalers that would produce monodisperse 
aerosol particles from drug solutions.  In these products, the mechanisms of droplet 
generation were based on either electrohydrodynamic atomisation (EHDA)3, or Rayleigh jet 
break-up.4  The EHDA based MysticTM pulmonary drug delivery system achieved geometric 
standard deviation (GSD) of 1.2,5 and the Rayleigh jet break-up based Medspray™ produced 
aerosol particles with the GSD of 1.4.4  A GSD of ≤1.22 for aerosol particles has been set as a 
criterion for monodispersity.6,7  Although the MysticTM pulmonary drug delivery system is 
capable of meeting this standard, the inhaler is a relatively complex device and requires a 
power supply.  Furthermore, the GSD of the MedsprayTM has been estimated to exceed 1.22.   
 
It should be noted that conventional inhalers have been the subject of recent investigation in 
the delivery of more advanced therapeutic agents to the body; here examples include 
monoclonal antibodies,8 lung anticancer drugs9 and genetic material.10  A drive currently 
exists to develop respirable therapeutic formulations for delivery to the body in order to 
effectively manage a range of local and systemic disease states.  We suggest that the efficacy 
of this route of delivery could be vastly improved if such compounds are efficiently delivered 
to pre-determined regions of the respiratory tract (i.e. using monodisperse particles of a 
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defined size).  Clearly, this could optimise treatment outcomes and importantly improve 
patient quality of life.  To reiterate, this would require knowledge of receptor sites and 
equivalency from one patient to another to be successful.  
 
An alternative approach to deliver monodisperse aerosol particles to the lungs via 
conventional inhalers would be to incorporate ingredients with narrow particle size 
distributions into formulations.11,12  However, previous work has served to demonstrate that 
in the case of conventional inhalers, in particular pressurised metered dose inhalers (pMDIs), 
the resulting aerosol particles may be clusters of primary drug particles.13,14  Nevertheless, it 
is not clear whether the respirable dose would improve compared to conventional inhalers by 
use of monodisperse particles, and also what fraction of delivered dose might be targeted to 
required regions of the lungs.   
 
To produce powders for inhalers, spray drying has been widely used.15,16  However, 
conventional spray dryers produce particles with a wide size distribution.  To overcome this, 
EHDA has been employed as the atomiser.17  Images acquired with scanning electron 
microscopy suggested that the EHDA spray drying system produced particles with size 
distributions narrower than conventional spray drying systems.17  Although in this work the 
GSD was not calculated, the size distribution of atomised droplets was in the range of 0-10 
µm with several droplets approximately 40 µm in diameter.  The presence of satellite droplets 
in an EHDA process has also been reported.18-21  To scale up the throughput of EHDA based 
atomisers, multiple nozzle systems have been developed.22-25  However, the scale-up of 
EHDA-based spray dryers has been impeded due to the complexity of the electrostatic field 
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arrangements applied to multiple jets, the specific requirements for the liquid properties and 
the relatively high cost to generate uniform droplets.26 
 
An alternative approach to produce uniform droplets for spray drying is by the inkjet method.  
There are two common modes for generating droplets, namely the continuous mode and 
drop-on-demand mode.27  In the continuous mode, a jet (stream) of liquid through an orifice 
(i.e. nozzle) is established and then with the help of a piezoelectric transducer the jet breaks-
up into droplets.  This process is called Rayleigh jet break-up, and if the piezoelectric 
transducer has a suitable frequency, then uniform droplets form.28  In this mode the droplets 
have diameters of approximately twice that of the nozzle diameter,29 and they typically travel 
at speeds as high as 25 m/s.30  For inkjet spray drying on a laboratory scale, the droplets may 
therefore not have enough time to dry before reaching the collecting vessel.    
 
With respect to the drop-on-demand mode, a piezoelectric transducer with an appropriate 
frequency and driving waveform generates pressure waves which eject uniform droplets from 
an inkjet nozzle.31  In this mode, the droplets have usually the same diameter as the nozzle 
orifice, and also travel much more slowly.  For inkjet spray drying on a laboratory scale, the 
droplets may therefore evaporate before reaching the cyclone or collecting vessel.   
 
Drop-on-demand devices are normally driven at frequencies below a threshold, which is 
printhead dependent, where each droplet is not greatly influenced by the preceding drop.  
However, under some circumstances such as in our experiments, where only regular streams 
of droplets are required, then much higher frequencies are possible. In these cases, the size 
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and velocity of the drops are frequency-dependent, being influenced by the complex 
interactions of the acoustics and fluid flows within the printhead.32,33   
 
An alternative method of ejecting droplets in the drop-on-demand mode is by the thermal or 
bubble-jet mechanism.  This employs a heating element in the printhead behind the nozzle 
that for a short period of time increases the solution temperature, in a very thin layer close to 
the heater, to the range of 350-400C.30  As a result, part of the solution vaporises, generating 
a pressure pulse which causes droplet ejection.  Although, the generation of monodisperse 
aerosol particles by the thermal inkjet method has been demonstrated,34 the atomising head is 
subject to rapid degradation, due to the high temperatures.30 
 
Inkjet spray drying based on the piezoelectric drop-on-demand mode has been previously 
employed for the production of uniform particles, but not for the sizes suitable for 
inhalation .35   In this approach the viscosity and surface tension of the feed solution should 
be in a suitable range, to ensure formation of uniform droplets without satellites.32  
Furthermore, spraying suspensions should be performed carefully in terms of particle size 
and concentration.  As drop ejection depends on receiving ultrasonic pressure waves intact to 
the tip of the nozzle, the presence of particles may alter the characteristics of the pressure 
waves and prevent droplet ejection.32   
 
The aim of this study was to explore the feasibility of targeting desired regions of the lungs 
more efficiently than conventional inhalers by using pMDIs that contain monodisperse 
primary drug particles.  In this work, piezoelectric inkjet devices were employed to produce 
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uniform droplets of drug solutions.  The inkjet devices had orifice diameters in the range of 1 
m to 22 µm and the devices were operated in the drop-on-demand mode.  The drug 
solutions were optimised to produce respirable particles in a spray drying system.  Then these 
particles were dispersed in a propellant to form suspension-based pMDIs.  The aerosol 
performances of pMDIs were evaluated by applying a compendial method and also the 
oropharyngeal models.   
 
Material and Methods  
 
Material 
Salbutamol sulphate was purchased from Bufa-Chemie (Castricum, The Netherlands), 
polyvinylpyrrolidone (PVP K30) from Sigma and Tween 20 from VWR Ltd.  
Hydrofluoroalkane 134a (Zephex 134a) was kindly supplied by Ineos Fluor (Runcorn, UK).  
Salbutamol sulphate suspension pMDI (Ventolin™ Evohaler™ GlaxoSmithKline Ltd, 
London, UK, 100 μg per actuation) was also employed.  Glycerol was obtained from BDH 
Laboratory Supplies, and Brij35 (polyoxyethylene (23) lauryl ether) was purchased from 
Sigma-Aldrich (Chemie GmbH, Steinheim, Germany).   
 
Formation of Uniform Droplets 
Commercially Available Inkjet Devices 
Droplets from drug (salbutamol sulphate) and excipient (PVP K30) solutions were produced 
by piezoelectric inkjet devices (Microfab, Texas, USA) with 5 µm or 10 µm orifice diameters.  
To prevent blockage of the nozzles, at least two membrane filters (Minisart, Sartorius Stedim, 
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Germany) were used with 0.2 µm pore size to filter the solutions prior to the inkjet devices.  
The devices were actuated at resonance frequencies by a frequency generator (Thurlby 
Thandar Instruments Ltd, Huntingdon, UK), or at 10 kHz frequency by using a Microfab 
frequency generator (Microfab, Texas, USA).  The resonance frequencies were detected by 
gradual changing the frequency until sudden formation of a straight jet was observed.  In all 
experiments double-sided square wave forms were used.  Droplets were illuminated by a 
strobe light and visualised with a macro lens (Navitar, Rochester, New York, USA) 
connected to a digital USB 2.0 camera (Alrad Imaging, Newbury, UK), with an image 
capture rate of 60 frames per second.     
 
In-House Made Inkjet Devices 
The commercial inkjet devices were not only prone to blockage, but also very fragile.  
Therefore, in-house inkjet devices were manufactured from more robust glass tubes, and easy 
to clean.  Then, the inkjet nozzles with orifice diameters of 1, 7, 14 and 22 m were made 
according to a previously reported method.36  The inkjet nozzle with orifice diameter of 14 
m was made from glass Pasteur pipette with the others from 2 mm capillary tubes.  In these 
devices, diaphragm piezoelectric disks (Farnell, Leeds, UK) were used, and a hole at the 
centre of the disk was drilled to accommodate the glass tube.  Conventional epoxy resin 
adhesives were used to hold the piezoelectric disk and glass tube together.   
In order to achieve a long term stable jet, the inkjet device with 7 m orifice diameter had 
three piezoelectric disks.  In this device, the first piezoelectric disk was placed at 2 mm 
distance from the tip of the nozzle and the other disks were attached at distances of 10 mm 
and 20 mm from the tip.  All the three piezoelectric disks were actuated with a single function 
generator.  However, the positive wires of the first and last (from the tip) piezoelectric disks 
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and the negative wire of the middle disk were connected to the positive lead of the function 
generator, with the reminder of the wires connected to the negative lead of the frequency 
generator.   
 
The operational conditions of inkjet devices are given in Table 1.  On inspection of Table 1, it 
is evident that satellite droplets appeared on occasions, which may be ascribed to the long 
term running of these devices.  However, this was rapidly corrected by adjusting the 
frequency of the inkjet device actuation.  It can be seen from Table 1 that all the experiments 
in this work are divided into two parts: those experiments in which there were satellite 
droplets during droplet formation process by the inkjet devices (formulations A to D), and 
those that satellite droplets were not noticed in the droplet formation process (formulations E 
to I).  This classification is followed for the rest of the paper to make comparing the results 
less complex.   
 
Spray Drying System 
A laboratory scale spray dryer, Buchi 190 (BÜCHI Labortechnik AG, Switzerland) was 
positioned horizontally so that the top of the equipment was inside a horizontal laminar flow 
cabinet.  A flexible tube was attached to the air inlet of the spray dryer and the other end was 
also placed inside the laminar flow cabinet.  These arrangements ensured the entrance of 
clean air (dust free) into the spray dryer.  The two-fluid nozzle was removed from the spray 
dryer and this allowed the droplets from the inkjet devices to enter the drying chamber.  For 
the 5 µm inkjet device, the inlet and outlet temperatures were 54 C and 32 C, respectively, 
but for the nozzles with orifices greater than this size, the inlet and outlet temperatures were 
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150 C and 70 C, respectively.  The air aspiration was set to the maximum in all experiments.  
A high performance cyclone was used to capture the particles.  Vial bottles (220 ml capacity) 
with 20 mm neck diameters were used as collecting vessels.   
 
The jet was short and fine from the 1 m (actual orifice diameter was 1.229 m) inkjet device 
(Figure 1).  Therefore, the device was placed inside a Perspex cabinet (41 × 45 × 35 cm, 
depth, width, height, respectively) to prevent deflection of the jet by air movements around 
the nozzle.  A 20 ml glass bottle was placed at 2 cm distance from the nozzle in a way that 
the jet would enter the container.  Initially two solution concentrations were tested: 5% and 1% 
(w/v).  However, crystal grains appeared inside the container when the 1% solution was used.  
Therefore, this concentration was not considered further.  In operating the 1 µm inkjet device, 
only the formation of the jet was achieved.  Due to the extremely small size of droplets, it 
was not possible to optimise the droplet formation process.   
 
The feed rate for the 1 m inkjet device was about 40l/hour.  For the inkjet devices with 
orifice diameters of 5, 7, 14, and 22 m, the feed rates were 0.07, 0.46, 2.0, and 2.5 ml/hour, 
respectively.  The feed rate was 1 ml/hour for the 10 µm inkjet device at 10 kHz frequency, 
but this increased to 3.5 ml/hour at the frequencies of 70 kHz and 125 kHz.   
 
The particle collection efficiency was approximately 10% in the current spray drying system.  
The particle deposition efficiency was also about 10% in the container by using the 1 m 
inkjet device.  This was due to the diffusion of submicron particles from the inside of the 
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container towards the outside.  A typical density of 1.3 g/cm3 was considered for produced 
particles. 
 
 
 
Scanning Electron Microscopy 
Spray dried particles were sputter coated with gold using an Emitech K550 (Ashford, UK) 
coater and then visualized with a Philips XL20 (Eindhoven, Holland) scanning electron 
microscope (SEM). 
 
Physical Particle Size Measurements 
The SEM images of particles were analysed for physical size measurements with the Scion 
Image Software, release Beta 3b (Scion Corporation, Maryland, USA).  For each sample a 
minimum of 600 particles were analysed.   
 
Preparation of Pressurised Metered Dose Inhalers 
When the collecting vessels of the particles contained at least 20 mg of drug/excipient 
powder, they were crimped with the Valois (Pharmaceutical division, Normandy, France) 
DF30 (50-µl metering chamber size) valves and filled with HFA 134a using a Pamasol 2016 
(Pamasol, Pfäffikon, Switzerland) laboratory scale manual crimper and propellant filler.  The 
drug concentration was in the range of 0.1-0.5 mg/g of the propellant.  The bottles were 
shaken vigorously to detach particles from internal surfaces.  The bottles were left for 3 days 
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at room temperature and humidity before commencing the aerosolisation studies.  Due to the 
considerably large size of the bottles, the Qvar (IVAX Pharmaceuticals, London, UK) 
actuator was sliced on the canister sleeve, 9 mm above the mouthpiece.  This allowed the 
connection of the (pMDI) valve to the nozzle of the actuator.  The actuator was able to 
perform reciprocal movements.  This actuator is referred as “actuator 1” in this paper.  In 
other sets of experiments, another actuator was also employed that was supplied by Presspart 
(Blackburn, UK).  This actuator had a rectangular mouthpiece with an orifice diameter 
(approximately 1 mm) significantly greater than that for the actuator 1.  The sleeve of this 
actuator was detachable.  This actuator is referred as “actuator 2” in this work. The inhalers 
were used with the actuator 1, unless otherwise stated.  The aim of using different actuators 
was to investigate the possibility of achieving aerosol particle size distributions similar to the 
primary particle size distributions.  The Ventolin Evohaler pMDI was used with its original 
actuator.   
 
After dispersion of powder formulations from Table 1 in HFA 134a, the pMDI formulations 
were given the same designations as the powder formulations. 
 
Aerodynamic Particle Size Measurements 
A Next Generation Impactor (Copley, Nottingham, UK) with the USP (United States 
Pharmacopeia) induction port was used for aerodynamic particle size measurements.  The 
surfaces of the impactor cups were coated with 0.5% Tween 20 solution in ethanol.  The 
ethanol was evaporated by drying the cups in an oven.  The impactor was connected to a high 
capacity air pump (Copley, Nottingham, UK) and air was drawn through at 30 L/min.  The 
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test inhaler was primed by three shots to the waste and was then connected to the impactor.  
In addition, the effects of spacers (small and large volumes) were evaluated by using a metal 
large spacer (Nebuchamber, AstraZeneca, Kings Langley, UK), and a small spacer 
(Optimiser, Norton Healthcare Ltd, Harlow, UK).  The aim of using spacers was to reduce 
aerosol particle aggregation in the aerosolisation experiments.  The inhaler was shaken and 
then connected to the induction port of the impactor and while air was being drawn through 
the inhaler, the device was actuated, and the airflow was maintained for 8 seconds.  For each 
aerodynamic particle size measurement the inhaler was actuated between 10 to15 times.  The 
impactor cups, the induction port and spacer (if used) were then washed with distilled water 
and the amounts of the drug were quantified by using spectrophotometric analysis at 276 nm 
from a standard curve.  The actuator was washed with distilled water and dried in an oven 
before each aerosolisation experiment.  The mass median aerodynamic diameter (MMAD) 
and GSD were calculated by plotting cumulative percentage of mass less than stated 
aerodynamic diameter (using log-probability scaling) versus aerodynamic diameter (log 
scale).  The experiments were performed under ambient conditions.  Each aerosolisation 
study was replicated six times.  The fine particle fraction (FPF) was defined as the percentage 
of the emitted dose that had an aerodynamic diameter less than 3.99 µm, i.e. from the stage 4 
of the impactor to the minimum orifice cup (MOC).  It should be noted that it was possible to 
fit actuator 2 only to the small spacer. 
 
In addition, six oropharyngeal models were employed as induction ports of the NGI.  The 
official NGI includes the USP induction port and the cups.  However, in this section the USP 
induction port was replaced with physiologically faithful oropharyngeal (mouth-throat) 
models.37   
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The characteristics of the oropharyngeal models are given in Table 2.  The models represent 
the oropharyngeal geometry of three subjects, each inhaling via two inhalers, one with a 
circular mouthpiece and the other with a rectangular mouthpiece.  Models with circular inlet 
at the oral cavity were used to evaluate an inhaler with actuator 1.  Models with rectangular 
inlet at the oral cavity were used to test the Ventolin Evohaler pMDI.  The models varied in 
terms of constrictions in the oropharynx, by models 1C and 2C being constricted at the 
oropharynx region, models 3A and 4A were wide open, and models 5B and 6B had moderate 
constrictions in that region.  Total volumes of the models gradually increased from model 1C 
to model 6B.  Oropharyngeal models 1C and 2C were obtained from one subject, 
oropharyngeal models 3A and 4A were acquired from another subject, and finally 
oropharyngeal models 5B and 6B belonged to the last subject.  
 
The models were made from ABS (acrylonitrile butadiene styrene) plastic. 38 The inside of 
each oropharyngeal model, prior to each experiment, was moisturised with a solution of 
glycerol and Brij 35 (70 mg in 100 ml).  To achieve this, the models were filled with the 
solution and then they were held up right for minimum of 30 minutes to allow leaving the 
excess solution from the models.  By this way, a thin film of the moisturising solution was 
formed on the internal surface of each oropharyngeal model.  The airflow through the models 
was also set to 30 L/min. In these experiments, an inhaler (without using a spacer) was 
connected directly to the oropharyngeal model, and an adaptor was employed to seal the 
connection between the mouthpiece of the inhaler and the oral cavity.  FPF was defined as 
the percentage of the emitted dose that deposited in the impactor.  It should be noted that 
aerosol particles with aerodynamic diameters greater than 3.99 µm tend to be captured by the 
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oropharyngeal models.  Therefore, different definitions of the FPF (depending on the type of 
the induction port) usually specify aerosol particles with similar aerodynamic diameters.  
Each experiment was replicated three times when the pMDI formulation contained 
monodisperse particles.  This was due to the availability of only limited amounts of 
monodisperse particles.  The number of replicates was six, when the Ventolin Evohaler 
pMDI was used.   
 
Statistical Analysis  
The non-parametric Kruskal-Wallis tests were conducted, which followed by the two-tailed 
Mann-Whitney U tests. The Bonferroni correction was applied to the alpha level.  There were 
10 comparisons in total, when the formulations were evaluated by using the NGI and USP 
induction port.  Then by applying the Bonferroni correction, the statistical significance level 
decreased to 0.005 (i.e. 0.05/10).  In this paper SD presents the standard deviation.  
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Results 
Formation of Uniform Droplets 
Figures 2A and 2B present images of droplets being generated from the 10 µm inkjet device 
at 70 and 125 kHz frequencies, respectively.  Figure 2B shows a column of the solution at the 
tip of the nozzle, which suggests the production of droplets larger than the nozzle orifice 
diameter.  However Figure 2A does not present that solution column at the tip, and this 
suggests the formation of droplets with diameters similar to the nozzle orifice diameter.  The 
absence of solution column was also observed for inkjet devices with orifice diameters of 7, 
14, and 22 µm (images not shown).  These findings indicated that the size of produced 
particles would also depend on the frequency of device actuation in the spray drying system.   
 
Morphology and Size Distribution of Primary Particles   
Figure 3 shows SEM images of primary particles manufactured by the inkjet spray drying 
system.  Figures 3A to 3D show non-uniformity of particle size for powder formulations A to 
D, respectively.  While, Figures 3E to 3I illustrate formation of near uniform particles for 
powder formulations E to I, respectively.   
 
The cumulative size distributions of the particles are illustrated in Figure 4A (powder 
formulations A to D) and Figure 4B (powder formulations E to I).   
 
The summary of statistical parameters is given in Table 3 for the primary particle size 
distributions.  The data suggest that the 10 m inkjet device produced the narrowest particle 
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size distribution (powder formulation I) at 10 kHz frequency (GSD of 1.05).  GSDs of less 
than 1.22 were also found for powder formulations E, G, and H (Table 3).  However, the 
GSD was above 1.22 when there were satellite droplets in the droplet formation process 
(powder formulations A to D), or actuating the inkjet device at 125 kHz (powder formulation 
F).  The aim of actuating the inkjet device at 125 kHz was to increase the powder production 
throughput compared to actuating the inkjet device at 70 kHz.  However, limited benefit was 
noted at these particular occasions.  As the solution feed rate remained relatively unchanged 
(3.5 ml/ hour) and also GSD increased by increasing the frequency.   
 
Physical Stability of pMDI Formulations 
The prepared formulations did not show signs of sedimentation for up to two months after 
preparation when the primary particles were prepared by the commercial inkjet devices 
(pMDI formulations B, E, F, H, I).  Figure 5A presents a typical example of these 
formulations three days after preparation.  However, the formulations did show precipitation 
within 24 hours after preparation (Figure 5B) when the primary particles were made by the 
in-house inkjet devices (pMDI formulations A, C, D, G).  It should be noted that the 
commercial inkjet devices had metal guards at the tip of the nozzle (indicated in Figure 2).  
Therefore, the variation in designs of inkjet devices might have affected on the physical 
properties of the particles and consequently on the physical stability of pMDI formulations.  
It appears that the aerosol performances of pMDI formulations were affected by the state of 
the physical stability of the pMDI formulations (data presented in the following section).  
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Aerodynamic Particle Size Distributions 
Evaluations with the USP Induction Port 
Figures 6A and 6B present the aerodynamic particle size distributions of the pMDI 
formulations within the impactor when a spacer was used, while Figure 6C shows the aerosol 
particle size distributions when the inhalers were used without a spacer.  Table 3 shows the 
summary of the cascade impaction data.   
 
The Effects of Spacer Devices 
Formulations E, G, H and I had primary particles with a GSD less than 1.22.  These showed 
low aerodynamic GSDs (i.e. ranging from 1.43 ± 0.10 to 1.63 ± 0.04), when these pMDIs 
were tested with the large spacer and actuator 1 (Table 3).  Conversely, pMDI formulations A 
to D contained polydisperse primary particles and they showed relatively greater 
aerodynamic GSDs (i.e. ranging from 1.59 ± 0.10 to 3.32 ± 0.37), when these formulations 
were evaluated with the large spacer and actuator 1.  Increasing the PVP proportion in the 
primary particles (powder formulations A to D, F and G in Table 1) did not make the 
aerodynamic GSD (pMDI formulations A to D, F and G) similar to the GSD of primary 
particles (Table 3).    
 
Figure 6B shows that pMDI formulations E to I (contained near monodisperse primary 
particles) had aerosol depositions in the range of 36.38 ± 2.50% to 41.75 ± 5.76% (of the 
emitted dose) on a single impactor stage.  While among pMDIs that contained polydisperse 
primary particles, maximum deposition on a single stage was 29.24 ± 4.2% (pMDI 
formulation B, stage 4, Figure 6A).  These formulations were evaluated with the large spacer 
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and actuator 1.  Here a similar trend was also observed for pMDI formulations C and G, 
when these were evaluated with actuator 1 but without a spacer (Figure 6C).  Formulation G 
showed significantly (P=0.002) higher aerosol deposition (27.77 ± 5.04%) on the stage 4 than 
pMDI formulation C on the same stage (10.80 ± 1.07%). 
 
The results presented in Table 3 indicate that the FPF of pMDI formulation F (66.29 ± 5.46%) 
was greater than that for pMDI formulation C (54.92 ± 3.83%), when these were evaluated 
with the large spacer and actuator 1.  Although the difference did not reach the significance 
level (P=0.015).  Furthermore, Figure 6B confirms that pMDI formulation F had 37.35 ± 2.76% 
of the emitted dose depositing on the stage 4, while this was 17.37 ± 2.16%  for pMDI 
formulation C (Figure 6A), when these formulations were evaluated with the large spacer and 
actuator 1.  These differences were despite of similarity of primary particles of pMDI 
formulation C and pMDI formulation F in terms of size (1.59 ± 0.38 µm and 2.03 ± 0.43 µm, 
respectively) and GSD (1.25 and 1.26, respectively).  Those dissimilarities in aerosol 
performances might be explained by the improved physical stability of pMDI formulation F 
compared to pMDI formulation C. 
 
The data in Figure 6B indicate that pMDI formulations E to H could be suitable for targeting 
the medium sized airways, while pMDI formulation I could target mainly the large 
conducting airways. 
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The Effects of Primary Particle Size Distribution (Polydisperse vs Monodisperse) 
It is apparent from Table 3 that pMDI formulation D had similar average primary particle 
size (2.39 µm) as powder formulation G (2.36 µm) and powder formulation H (2.65 µm), but 
the primary particle size distribution in pMDI formulation D was wider (GSD of 1.45) than 
those for pMDI formulation G (GSD of 1.14) and pMDI formulation H (GSD of 1.14).  
Evaluating these pMDI formulations with the large spacer and actuator 1 indicated that drug 
deposition in the spacer was much higher for pMDI formulation D (48.67 ± 5.20%) than 
those for pMDI formulation G (21.98 ± 16.84%) and pMDI formulation H (25.22 ± 7.43%) 
(Figures 6A and 6B).  Furthermore, pMDI formulation G had significantly greater FPF (59.18 
± 12.73%, Table 3), smaller MMAD (2.05 ± 0.20 m) and aerodynamic GSD (1.63 ± 0.04) 
compared to pMDI formulation D (27.32 ± 1.70%, 3.22 ± 0.50 m, 2.48 ± 0.70, respectively) 
(P=0.002).  Likewise, pMDI formulation H had significantly greater FPF (46.67 ± 2.06%) 
and smaller aerodynamic GSD (1.48 ± 0.11) than those for pMDI formulation D (P=0.002).  
These observations indicate that pMDI formulations with monodisperse primary particles 
would have significantly higher FPFs and smaller aerodynamic GSDs than those for pMDI 
formulations with polydisperse primary particles.  In particular, when the primary particles 
are in the range of 2.36 ± 0.34 µm to 2.65 ± 0.34 µm.   
 
Table 3 indicates that pMDI formulations A, B, E and F achieved FPFs greater than 60%, 
when these were examined with the large spacer and actuator 1.  Primary particles gradually 
increased in size from 0.65 ± 0.28 µm to 2.03 ± 0.43 µm in the order of pMDI formulation 
A<B<E<F, but FPFs remained relatively unchanged.  For example, the FPF of pMDI 
formulation A (68.94 ± 6.22%) was not statistically different (P=0.589) from FPF of pMDI 
formulation F (66.29 ± 5.46%).  Interestingly, the GSD of primary particles decreased from 
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1.60 to 1.07 in the order of pMDI formulation A<B<F<E.  These observations indicate that if 
pMDI formulations contain polydisperse primary particles, then these formulations may 
achieve high FPFs if average primary particle size becomes close to 1.15 µm or even 0.65 µm.   
 
The Aerosol Performance of Submicron Primary Particles 
Table 3 shows that pMDI formulation A had MMADs considerably greater than the size of 
primary particles (0.65 ± 0.28 µm) with or without using the large spacer (2.20 ± 0.36 µm, 
and 2.30 ± 0.43 µm, respectively).  Furthermore, Figure 6A shows that the drug deposition 
(27.51 ± 4.81%) was the highest on the stage 5 (cut off diameter 1.36 µm) for this 
formulation.  These observations suggest that most of aerosol particles were made of clusters 
of small primary particles.  Then this aggregated nature of aerosol particles contained 
considerable amount of void space.  Therefore, the FPF of pMDI formulation A with the 
large spacer (68.94 ± 6.22%) or without a spacer (53.95 ± 4.59%, Table 3) became 
significantly greater than those for a conventional  pMDI such as the Ventolin with the large 
spacer (57.32 ± 1.31%, P=0.004) or without a spacer (33.48 ± 1.91%, P=0.002).   
 
 
Comparison of Actuators  
Figures 6A and 6C show that aerosol depositions reduced considerably on impactor stage 1, 
stage 2, and stages 6 to MOC by using actuator 2 for pMDI formulation C, compared to 
aerosol depositions on those stages by using the actuator 1.  As a result the GSDs of aerosol 
particles from pMDI formulation C used with actuator 2 were smaller than those for pMDI 
formulation C used with actuator 1 (Table 3).  However, actuator 2 also reduced considerably 
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FPFs, compared to those FPFs by using actuator 1 (Table 3).  These findings show that the 
type of actuator had paramount effects on the aerosol performances of pMDIs.   
 
Evaluations with the Oropharyngeal Models 
Figure 7A presents aerosol depositions in the impactor by using the oropharyngeal models 
(2C, 4A, 5B) for pMDI formulation G (containing monodisperse primary particles with 
diameter of 2.36 ± 0.34 µm).  Upon inspection of Figure 7A, it is evident that stage 4 showed 
maximum drug deposition, as formulation G showed with the USP induction port (Figure 6C).  
Figure 7A also shows that the amount of drug deposited on the stage 4 increased by 
increasing the oropharyngeal volume.  The drug deposition on the stage 4 was 5.91 ± 4.84% 
of the emitted dose.  However, the drug deposition was spread mostly from the stage 4 to 
stage 6 for a conventional polydisperse pMDI such as the Ventolin (Figure 7B).  The stage 5 
showed maximum aerosol deposition (3.13 ± 1.65% of the emitted dose).   
 
The summary of cascade impaction data for the oropharyngeal models is given in Table 4.  
Data in Table 4 show that the aerodynamic GSDs of pMDI formulation G were smaller 
(ranging from 1.18 ± 0.11 to 1.28 ± 0.03) than the aerodynamic GSD of this formulation 
when it was evaluated with the USP induction port but without a spacer (2.36 ± 0.64, Table 
3).  Furthermore, pMDI formulation G showed GSDs considerably smaller than the GSDs of 
the Ventolin (ranging from 2.37 ± 0.19 to 2.81 ± 0.26), when these formulations were 
examined with the oropharyngeal models (Table 4).  However, the average FPF (9.88 ± 
6.10%) of all three oropharyngeal models for pMDI formulation G was comparable to the 
average FPF (9.60 ± 4.58%) of all three oropharyngeal models for the Ventolin.  These 
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observations suggest that pMDIs with monodisperse primary particles may target desired 
regions of the lungs more effectively than pMDIs with polydisperse primary particles. 
 
Morphology and Size of Primary Particles After Dispersion in HFA 
Aerosol depositions (about 10% of the emitted dose) were not expected on the MOC stage 
(cut off diameter less than 0.54 µm) of the impactor from pMDI formulation G (Figures 6B, 
6C, 7A).  This expectation was based on the fact that all of primary particles being greater 
than 1 µm.  To investigate further, the HFA was evaporated from pMDI formulation G, and 
then the residual powder was examined by SEM.  It was found that the primary particles of 
pMDI formulation G had particle size of 2.39 ± 0.32 µm with the GSD of 1.14 after 
dispersion in HFA 134a.  These particles had sizes similar to the primary particles of pMDI 
formulation G before dispersion in the propellant (2.36 ± 0.34 µm, GSD of 1.14, Table 3).  
Figure 8 compares SEM images of primary particles of pMDI formulation G before and after 
dispersion in HFA 134a.  It can be seen that physical diameters and the surface morphology 
of the primary particles remained relatively unchanged after dispersion in HFA 134a.  By 
considering that only 10% of primary particles had a size in the range of 1.8 µm to 2.07 µm, 
then the aerosol deposition on the MOC stage could be due to these primary particles.   
 
Discussion 
This study showed that primary particle size and particle size distribution had significant 
effects on the aerosol performances of suspension pMDIs, and indeed inkjet spray drying 
may be useful in producing primary particles with a desired size.    
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This study suggests that to achieve a pMDI with relatively high FPF then for primary 
particles in the range of 1.59 µm to 2.03 µm, the GSD should be less than 1.25, and for 
primary particles greater than 2.03 µm, the GSD should be less than 1.14.  If the desired GSD 
of primary particles is approximately 1.45, then the sizes of these particles should be in the 
region of 1.15 µm. 
 
This study found that pMDIs with monodisperse drug particles had increased fine particle 
fractions and also narrower aerodynamic particle size distributions compared to a formulation 
with similar average primary particle size but being polydisperse.  The aerodynamic GSDs of 
pMDI formulations prepared with monodisperse particles were greater than the GSDs of the 
primary particles.  Perhaps this would be expected by considering the polydisperse nature of 
propellant droplets generated during aerosolisation.13,14  However, the monodisperse pMDIs 
delivered up to 40% of the emitted dose to a single stage of the NGI when the USP induction 
port, a large volume spacer and an actuator with 0.3 mm orifice diameter were used.   
 
Previous studies39,40 showed much narrower aerosol particle size distributions for pMDIs 
containing 5 µm polystyrene particles than the pMDI in this study that contained 4.99 µm 
monodisperse salbutamol sulphate particles.  Then a smaller GSD might have been achieved 
in this study, if the formulation would have been optimised further in terms of surfactant type, 
valve size and the volume of spacer.   
 
It should be noted that asthma is a highly complex disease.  Only recent studies have shown 
distinct asthma phenotypes, which may require distinct therapeutic approaches and agents.41  
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If the chosen therapeutic agent has significant side effects, then a monodisperse inhaler could 
benefit the patient by reducing the dose of inhaled drug required to obtain the equivalent 
clinical outcome. 41 
 
The respirable doses determined by the oropharyngeal models in this study were similar to 
clinical data determined for the Ventolin Evohaler,42 and these were less than those 
determined by using the USP induction port with the cascade impactor.  Also, the respirable 
doses of the oropharyngeal models were less than those for the USP induction port for a 
pMDI containing monodisperse primary particles.  However, the results of this study found 
that certain subjects (those with large volume oropharynx and moderately constricted during 
inhalation) could receive considerably more respirable doses by using pMDIs containing 
monodisperse particles than conventional pMDIs.  For other subjects, the amounts of 
respirable doses may not increase by using pMDIs containing monodisperse particles, but the 
deposition of aerosol particles could be accumulated in certain and perhaps desired regions of 
the lungs. 
 
The aerosol particle size distribution data for a pMDI formulation that contained submicron 
primary particles suggested that the use of submicron particles may not be the solution to 
target the alveoli by suspension pMDIs.  The results of this study suggested that primary 
particles with physical diameters in the range of 1.8 µm to 2 µm with extensively corrugated 
surfaces may target peripheral lungs or alveoli by using suspension pMDIs. 
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In this study a single inkjet device was used for spray drying, while for production at an 
industrial scale or even for small batch sizes at the pilot scale, a multi-nozzle system would 
be required.  To achieve a multi-nozzle system for inkjet spray drying, micro-nozzle plates43 
or droplet-ejector nozzle arrays44,45 could be potential starting points.  Then existence of these 
systems would allow producing powders with a sufficient amount to evaluate the effects of 
particle size uniformity on powder properties such as powder flow.   
 
The particles manufactured in this study had narrower size distributions than the results of 
Patel and Chen 2007.35  This could be due to differences in the orifice diameters of the inkjet 
nozzles.  The orifice diameter of the nozzle in the previous study was 80 µm, whereas in this 
study they were in fact smaller.  Therefore, the narrower particle size distributions could be 
explained by the fact that the droplets from smaller nozzles were dried faster than droplets 
from the larger size nozzle.  This would provide less time and thus opportunity for the 
droplets to merge.  Increasing the drying chamber size and scattering droplets with the help of 
an air diffuser resulted in the production of monodisperse particles from a 75 µm orifice 
diameter inkjet device.46   
 
The formulations developed in this study did not contain ethanol to disperse the particles.  
Also, relatively large amounts of propellant were introduced into the pMDI bottles.  
Therefore, further studies are required to determine whether the presence of ethanol or 
increasing the formulation solid content would influence on the aerosol performances of the 
inhalers.47,48   
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Part of inhalers in this study showed a significant improvement in physical stability compared 
to those reported previously.49  This might be explained by the presence of electrostatic 
charges on the particles.  This explanation may be supported by the fact that the inkjet 
method allows charging of the ejected droplets.  This is frequently applied in the printing 
industry, when the mode of droplet formation is the continuous mode.27  We propose that an 
avenue for further study would involve preparing monodisperse particles with different levels 
of electrostatic charges and using these in formulations of suspension pMDIs.  This step 
would be followed by measuring the electrostatic charge of aerosol particles by previously 
reported methods50 and evaluating physical stability together with the aerosol performance.   
 
Aerodynamic particle size analysis plays a key role for manufacturers not only for quality 
control purposes, but also to maintain the efficacy of the product.  Therefore, less batch-to-
batch variation could be another expectation of using uniform primary particles in the 
manufacture of orally inhaled suspension drug products.  In particular, this may lead to 
achieving reproducible measurements of aerodynamic particle size distributions using 
cascade impactors, batch after batch. 51 In addition, the use of monodisperse particles at 
industrial scale would aid in understanding and optimisation of the manufacturing process.  
Therefore, the use of monodisperse particles may help better implementation of the quality by 
design (QbD).  Also, the use of monodisperse particles would reduce variation in the raw 
material, which would ensure that quality is built into pharmaceutical products.52  
Furthermore, the ability to produce monodisperse primary particles in an industrial scale and 
using them in the formulation of an inhaler may provide unique properties to the product that 
could be challenging for competitors to match the product after the product is off the patents. 
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In this work an inkjet device was used that had triple piezoelectric components and the orifice 
diameter was 7 µm.  This device showed much improved jet stability over a long term run 
compared to a device with single piezoelectric component and similar orifice diameter.  This 
observation might be explained that in the triple disk inkjet device the negative pressures 
were much stronger than those in the single piezoelectric inkjet device.32  Therefore, if small 
particles in the feed solution were about to interfere with the droplet formation process, then 
(in the triple disk inkjet device) they were removed with a strong force away from the nozzle 
orifice.   
 
Conclusions 
This study demonstrated significant improvement in the fine particle fraction (FPF) of 
pressurised metered dose inhalers (pMDIs) that contained monodisperse primary particles 
compared to FPF of pMDIs that contained similar average primary particle size but being 
polydisperse.  Furthermore, pMDIs with monodisperse primary particles may target regions 
of the lungs more effectively than conventional inhalers. 
 
This study found that to achieve a high FPF, for primary particles with average size in the 
range of 0.65 µm to 1.15 µm the GSD could be high in the range of 1.45 to 1.60.  While for 
primary particles with average size in the range of 1.5 µm to 2 µm, the GSD should be less 
than 1.25; and for primary particles greater than 2µm, the GSD should be less than 1.14.  An 
actuator with orifice diameter of 0.3 mm played an important role for delivery of high FPFs.  
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The results of this study suggest that the inkjet spray drying may be used to achieve primary 
particles with precise size.  Furthermore, the inkjet method may provide additional 
optimisation of particles and then achieving suspension pMDIs with significantly improved 
physical stability. 
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List of Figures 
Figure 1. A photograph of the 1 µm inkjet device while emitting droplets.  The piezoelectric 
disk and tip of the nozzle are indicated. 
 
Figure 2. Stroboscopic images of droplet formation via the 10 µm inkjet device at 
frequencies: A) 70 kHz, B) 125 kHz.  The metal guard is shown and the formation of fluid 
column at the tip of the nozzle is also indicated.   
 
Figure 3.  Panels A to D, SEM images of particles for powder formulations A to D, which 
contained polydisperse particles.  Panels E to I, SEM images of particles for powder 
formulations E to I, which contained near-uniform particles.  
 
Figure 4.  A) Cumulative under size distributions for powder formulations A to D that 
contained polydisperse particles.  B) Cumulative under size distributions for powder 
formulations E to I that contained near-uniform particles.   
 
Figure 5. A) Presenting physical stability of a pMDI that the primary particles were prepared 
by the 10 µm inkjet device, which had metal guards. This picture was taken three days after 
preparation of the pMDI.  B) Illustrating the sedimentation of the primary particles the next 
day after preparation, in a pMDI that the primary particles were produced by an in-house 
inkjet device.  The primary particles were made by the 7 m inkjet device, which did not 
have metal guards. 
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Figure 6.  Drug deposition distributions of pMDI formulations in the Next Generation 
Impactor with the USP induction port.  A) Using a spacer, pMDI formulations contained 
polydisperse primary particles.  B) Using a spacer, pMDI formulations contained near 
monodisperse primary particles.  C) Formulations were evaluated without a spacer.  Error 
bars present standard deviations (n=6).   
 
Figure 7. A) Drug deposition distributions of pMDI formulation G (prepared with 
monodisperse primary particles) in the Next Generation Impactor with the oropharyngeal 
models: 2C, 4A and 5B.  B) Drug deposition distributions of the Ventolin in the Next 
Generation Impactor with the oropharyngeal models: 1C, 3A, and 6B.  Error bars present 
standard deviations.  Data labels are also indicated.  The key to symbols also shows the 
corresponding oropharyngeal volume. 
 
Figure 8.  The SEM images of primary particles of pMDI formulation G (prepared with 
monodisperse primary particles), A) before and B) after dispersion in HFA 134a.    
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Table 1: Operational conditions of the inkjet devices to produce droplets. 
Powder 
Formulation 
Inkjet 
Orifice 
Diameter
/µm 
Feed Solution 
Concentration 
(w/v)  
Salbutamol 
Sulphate:PVP 
Ratio 
Peak-to-
Peak 
Voltage/V 
Frequency
/ 
kHz 
Presence of 
Satellite 
Droplets 
A 1 5% 50:50 20 74 Yes 
B 5 0.3% 50:50 22 80 Yes 
C 7 0.1% 50:50 8 103 Yes 
D 22 0.1% 50:50 20 105 Yes 
E 10 0.05% 75:25 22 70 No 
F 10 0.05% 50:50 22 125 No 
G 14 0.1% 50:50 20 85 No 
H 10 0.1% 75:25 22 125 No 
I 10 0.3% 75:25 60 10 No 
 
 
Table 2: The Characteristics of the oropharyngeal models.   
Subject Gender Oral Cavity 
Inlet Cross 
Section 
Oropharyngeal 
Opening 
Total 
Volume 
(cm3) 
Oropharyngeal 
Model 
Designation 
Evaluated 
Formulation 
I Female 
Rectangular Constricted 37.6 1C Ventolin 
Circular Constricted 53.4 2C Monodisperse 
II Male 
Rectangular Wide 55.9 3A Ventolin 
Circular Wide 68.4 4A Monodisperse 
III Male 
Circular Moderate 75.1 5B Monodisperse 
Rectangular Moderate 80.8 6B Ventolin 
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Table 3.  The summary of statistical parameters for primary particle size distributions, and 
the summary of cascade impaction data, when pMDI formulations were evaluated with the 
USP induction port. 
pMDI 
Formulation 
Primary 
Particle 
Diameter/µm 
(mean ± SD)  
Primary 
Particle 
GSD 
Actuator Spacer MMAD/µm 
(mean ± SD) 
Aerodynamic 
GSD 
(mean ± SD) 
%FPF 
(mean ± SD) 
A 0.65 ± 0.28 1.60 1 
Large 2.20 ± 0.36 2.08 ± 0.42 68.94 ± 6.22 
- 2.30 ± 0.43 2.92 ± 0.23 53.95 ± 4.59 
B 1.15 ± 0.42 1.45 1 Large 2.34 ± 0.35 1.59 ± 0.10 64.80 ± 6.65 
C 1.59 ± 0.38 1.25 
1 Large 2.35 ± 0.43 3.32 ± 0.37 54.92 ± 3.83 
2 Small 2.55 ± 0.37 2.04 ± 0.49 22.42 ± 3.77 
1 - 2.56 ± 0.31 4.71 ± 0.95 44.43 ± 8.70 
2 - 3.05 ± 0.48 2.48 ± 0.48 21.46 ± 2.78 
D 2.39 ± 0.68 1.45 1 Large 3.22 ± 0.50 2.48 ± 0.70 27.32 ± 1.70 
Ventolin Not determined Original 
Large 2.40 ± 0.30 1.74 ± 0.14 57.32 ± 1.31 
- 2.56 ± 0.16 2.16 ± 0.10 33.48 ± 1.91 
E 1.76 ± 0.13 1.07 1 Large 2.30 ± 0.30 1.50 ± 0.10 69.78 ± 2.89 
F 2.03 ± 0.43 1.26 1 Large 2.69 ± 0.68 1.86 ± 0.37 66.29 ± 5.46 
G 2.36 ± 0.34 1.14 1 
Large 2.05 ± 0.20 1.63 ± 0.04 59.18 ± 12.73 
- 2.00 ± 0.44 2.36 ± 0.64 49.31 ± 8.16 
H 2.65 ± 0.34 1.14 1 Large 3.09 ± 0.88 1.48 ± 0.11 46.67 ± 2.06 
I 4.99 ± 0.28 1.05 1 Large 4.73 ± 1.68 1.43 ± 0.10 4.43 ± 3.99 
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Table 4.  Summary of the cascade impaction data when pMDI formulation G (prepared with 
monodisperse particles) and the Ventolin were evaluated by using the oropharyngeal models.  
 
Oropharyngeal 
Model 
Evaluated 
Formulation 
MMAD/µm 
(mean ± SD) 
GSD 
(mean ± SD) 
%FPFa 
(mean ± SD) 
1C Ventolin 2.02 ± 0.96 2.81 ± 0.26 5.87 ± 0.81 
2C Monodisperse 2.29 ± 0.68 1.18 ± 0.11 3.51 ± 3.05 
3A Ventolin 2.00 ± 0.16 2.39 ± 0.11 14.72 ± 2.00 
4A Monodisperse 1.66 ± 0.75 1.28 ± 0.03 10.43 ± 0.42 
5B Monodisperse 1.69 ± 0.22 1.27 ± 0.05 15.69 ± 5.51 
6B Ventolin 1.96 ± 0.18 2.37 ± 0.19 8.23 ± 2.25 
 
aFPF (percent of the emitted dose that deposited in the impactor). 
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